[{"id":"96e07c94-7a83-4ec3-b148-9faedc5d7126","acronym":"HFB-200301-01","url":"https://clinicaltrials.gov/study/NCT05238883","created_at":"2022-02-14T15:52:46.465Z","updated_at":"2024-07-02T16:35:06.647Z","phase":"Phase 1","brief_title":"A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05238883 - HFB-200301-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • emunkitug (HFB200301)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"}]